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A B S T R A C T
Objectives: Luteinizing hormone-releasing hormone (LHRH) agonists represent one of the
main cost factors in themanagement of patients with metastatic prostate cancer. We com-
pared the cost-effectiveness of the five different 3-month formulations of LHRH agonists
currently available for advanced prostate cancer in Italy, because these differ both in their
capacity to suppress testosterone and in their acquisition costs.
Methods: A probabilistic, patient-level simulation model was developed to compare the
cost-effectiveness, from the perspective of the Italian National Health Service (INHS), of
leuprorelin 11.25 mg and 22.5 mg, triptorelin 11.25 mg, buserelin 9.9 mg, and goserelin 10.8
mg. Themodel incorporated testosterone-dependent progression-free and cancer-specific sur-
vival functions, LHRH agonist effectiveness data, and national costs and tariffs. Cox’s propor-
tional hazardmodelswereused to compute total andprogression-free survival functions based
on clinical data from 129 patients with metastatic prostate cancer treated in an Italian center.
Bayesian random effects models were employed to summarize evidence from published liter-
ature on testosterone suppression obtained with the available LHRH agonists.
Results: Estimated total survival was5 years, with a maximum difference between treat-
ment options of 2 months. There was a mean difference of almost €2,500 in lifetime total
costs between the least costly option (leuprorelin 22.5 mg) and the most expensive (gose-
relin). In the incremental cost-effectiveness analysis, leuprorelin 22.5 mg dominated all
alternatives except buserelin, which had an incremental cost-effectiveness ratio versus
leuprorelin 22.5 mg of €12,000 per life-month gained.
Conclusions: Based onmodelling withmeta-analysis of comparative survival data, leupro-
relin 22.5mgwas themost cost-effective treatment of the available depot formulation LHRH
agonists.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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rostate carcinoma is the second most common tumor in Italy,
econd only to lung cancer, with an estimated incidence of
2,804 cases in 2005 (total male population of 28,376,804, of
hich 4,717,170 were older than 65 years of age), representing
ig. 1 – Simplified structure of the model, represented as a d
ranch, the simulation is conducted using a Markov chain. F
epresented. pCancerDeath, probability of cancer-related dea
isease progression.
Table 1 – Clinical parameters included in the cost-effective
Variable
Mean baseline characteristics of the patient cohort
PSA at 6 months, ng/ml
Gleason score
Age, years
Cox’s proportional hazard model 1: coefficients of time to
biochemical relapse
Gleason score*
Ln PSA at 6 months†
Testosterone level at nadir2*
Cox’s proportional hazard model 2: coefficients (SD) of
cancer-specific survival after relapse
Gleason score†
Ln PSA at 6 months†
Testosterone at nadir2†
LHRH agonist
Meta-analysis results: nadir testosterone concentrations (ng/dl)
Goserelin
Leuprorelin 3.75/11.25 mg (Enantone®)
Leuprorelin 7.5/22.5 mg (Eligard®)
Buserelin
Triptorelin
Ln, logarithm; PSA, prostate-specific antigen; SD, standard deviation
* P  0.05.
† P  0.01.7% of all diagnosed cancers. Furthermore, it is the third most
ommoncancer-related cause of death, after lung and colorectal
ancers. In 2005 there were 9070 deaths from prostate cancer in
taly, corresponding to 7% of total cancer mortality [1,2].
Although, to the best of our knowledge, no comprehensive
ost-of-illness study is available for prostate cancer in Italy, a
onal tree, with evaluated treatment options. In each
implicity, only the leuprorelin 22.5-mg branch is fully
Death, probability of death; pProgression, probability of
model.
Mean or coefficient SD
185.8 344.1
7.0 1.5
74.6 6.7
0.173 0.081
0.336 0.046
2.346 1.153
0.291 0.101
0.208 0.051
3.998 1.30
Mean SD
18.41 6.95
13.45 3.02
9.09 2.86
8.48 3.97
10.72 4.85ecisi
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82 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 - 8 9ecent multinational study assessed the direct initial health
are costs during the first year after diagnosis. For Italy, the
stimate was approximately €5200 per patient, leading to an
stimated annual cost of €202 million for newly diagnosed
atients alone [3].
In cases of metastatic prostate cancer, luteinizing hor-
one-releasing hormone (LHRH) agonist monotherapy is the
rst-line treatment recommended by Italian guidelines, given
hat Italian patients generally refuse surgical castration and
hat there is no evidence that combined androgen blockade is
uperior [4].
Table 2 – Analysis of comparative efficacy of different LHRH
with metastatic prostate cancer.
Authors [reference] LHRH agonist N
Mean Med
Waxman et al. [10] Buserelin‡ 4 6.2 N
Chander et al. [25] Buserelin† 69 13.6 N
Pettersson et al. [26] Buserelin‡ 21 5.5 4
Kaisary et al. [11] Goserelin* 148 36.3 N
Fernandez del Moral
et al. [12]
Goserelin* 83 17.3 N
Fernandez del Moral
et al. [12]
Goserelin‡ 77 17.9 N
Debruyne et al. [13] Goserelin*,# 38 15.3 N
Debruyne et al. [13] Goserelin‡,# 42 19.4 N
Debruyne et al. [13] Goserelin*,** 39 19.2 N
Debruyne et al. [13] Goserelin‡,** 41 18.8 N
Yri et al. [28] Goserelin‡ 25 NR 26
Fontana et al. [21] Goserelin‡ 120 11.3 N
Fujii et al. [29] Goserelin* 50 10.0 7
Sarosdy et al. [16] Goserelin‡ 59 17.5 33
Fujii et al. [29] Goserelin‡ 74 12.0 10
Crawford et al. [27] Leuprorelin (Eligard) 103 12.3 N
Oefelein [14] Leuprorelin (Eligard)‡ 13 NR 10
Oefelein [15] Leuprorelin (Eligard)‡ 32 NR 10
Oefelein and
Cornum [17]
Leuprorelin (Eligard)‡ 38 NR N
Fowler et al. [18] Leuprorelin (Eligard)¶ 80 9.3 N
Chu et al. [19] Leuprorelin (Eligard)‡ 111 10.1 N
Perez-Marreno
et al. [20]
Leuprorelin (Eligard)* 118 6.1 4
Sartor et al. [22] Leuprorelin (Eligard)§ 90 12.4 N
Heyns et al. [23] Leuprorelin (Eligard)* 140 4.1 N
Heyns et al. [23] Triptorelin* 137 4.3 N
Teillac et al. [24] Triptorelin* 68 13.9 N
Teillac et al. [24] Triptorelin‡ 63 13.9 N
Yri et al. [28] Leuprorelin (Enantone)‡ 40 NR 17
Fujii et al. [29] Leuprorelin (Enantone)* 40 11.0 8
Fujii et al. [29] Leuprorelin (Enantone)‡ 68 12.0 9
Max, maximum; Min, minimum; NR, not reported; SD, standard devi
* 1-month depot
† 2-month depot
‡ 3-month depot
§ 4-month depot
 6-month depot
¶ 1-year depot
# Study I** Study IIThe rationale for anti-androgen therapy in prostate cancer
s the observation that testosterone represents an essential
rowth stimulus for prostatic cancer cells during much of the
iological history of this tumor. LHRH agonists modulate the
hysiological feedback mechanism along the hypothalamic-
ituitary-gonadal axis, with consequent suppression of testic-
lar testosterone production.
The judgment on the optimum testosterone level to be
eached for suppressing the growth of prostatic cancer cells
as evolved alongside the detection ability of the assays used
o determine serum testosterone concentrations: whereas the
nists in lowering serum testosterone levels in patients
Serum testosterone, ng/dl
SD Min Max Percentile
2.5%
Percentile
97.5%
Cutoff Patients
within
cutoff, %
NR 0 15.0 NR NR 72.1 100
NR NR NR NR NR NR NR
5.3 2.0 26.0 2 19 50–20 100–95
NR NR NR NR NR NR NR
11.2 NR NR NR NR 58 100
14.1 NR NR NR NR 58 98.8
NR NR NR NR NR NR NR
NR NR NR NR NR NR NR
NR NR NR NR NR NR NR
NR NR NR NR NR NR NR
NR 14.4 63.5 NR NR 81 100
NR NR NR NR NR 58 100
NR NR NR 5.1 13.1 50 100
NR NR NR NR NR 50 100
NR NR NR 5.1 14.9 50 98.6
2.1 NR NR NR NR 50–20 99–88.3
11.0 1.0 130.0 4 49 20 92.0
NR 10.0 40.0 10 20 20 NR
NR NR NR NR NR 50–20 95–87
NR NR NR NR NR 50 98.8
0.1 NR NR NR NR 50–20 100–94
NR 3.0 27.0 NR NR 50–20 100–97.5
0.8 NR NR NR NR 50–20 98–90
NR 0 10.3 NR NR 50 97.3
NR 0 8.3 NR NR 50 98.8
NR NR NR 7.2 20.8 50 96.0
NR NR NR 6.0 20.8 50 98.0
NR 14.4 271.1 NR NR 81 90.0
NR NR NR 5.0 13.8 50 95.0
NR NR NR 5.9 14.8 50 98.5
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83V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 - 8 9raditional threshold was set at 50 ng/dl (“castration level”),
ith the introduction of more sensitive assays, it was lowered
o 20 ng/dl. Nowadays, immunoassays are able to detectmuch
ower concentrations, allowing investigating more accurately
he relationship between circulating testosterone levels and
linical outcomes in patientswithmetastatic prostatic cancer.
ecently, a continuous relationship between the risk of can-
er-related death and serum testosterone levels has been
emonstrated [5].
Five different depot formulations of LHRH agonists are cur-
ently available in Italy, for administration either once
onthly or every 3 months. A recent review suggests that
hese have differing capacities to lower testicular production
f testosterone, but all induce high rates of “castration” levels
50 ng/dl) [6]. Once-monthly formulations have a higher ac-
uisition cost per milligram than the corresponding 3-month
oses, which have been approved on the basis of noninferior-
ty studies. An expert roundtable discussion concluded that
LHRH agonists should be considered first-choice testoster-
ne-lowering therapy for the treatment of prostate cancer,
ith the 3-month depot formulation providing optimal con-
enience and flexibility” [7].
In order to establish the most cost-effective option
mong LHRH agonists, an economic analysis was performed
o compare the 3-month options: leuprorelin 11.25 mg and
2.5 mg, triptorelin 11.25 mg, buserelin 9.9 mg, and gose-
elin 10.8 mg. The aim of this work was the pharmacoeco-
omic comparative evaluation of 3-month LHRH agonist
reatments for metastatic prostate cancer, from the per-
Table 3 – Pharmaceutical costs.
LHRH agonist Brand
Leuprorelin 11.25 mg Enantone 3-month depot
Leuprorelin 22.5 mg Eligard 3-month depot
Goserelin Zoladex 3-month depot
Triptorelin Decapeptyl 3-month depot
Buserelin Suprefact 3-month depot
Table 4 – Costs considered in the model.
Item Cost
LHRH agonist ex-factory acquisition costs, €/package
Leuprorelin 11.25 mg 278.80
Leuprorelin 22.5 mg 234.78
Goserelin 358.91
Triptorelin 317.85
Buserelin 247.99
Follow-up examinations, €/year
Medical examination plus DRE 41.32
PSA, hematology, blood chemistry 82.76
Bone densitometry 31.50
Cardiology evaluation (visit plus ECG) 32.28
Abdominal sonography 120.86
Bone scintigraphy (total body) 226.20
Therapy for the hormone-refractory phase, €
Chemotherapy and adverse events management 9475.58
DRE, digital rectal examination; ECG, electrocardiogram; PSA,M
prostate-specific antigen.pective of the Italian National Health Service (INHS). The
valuation was performed by developing a model to simu-
ate testosterone levels obtained with these therapies and
he correlation between these levels and the risk of cancer-
elated death.
ethods
odel description and transition probabilities
linical data used to compute total and progression-free
urvival were extracted from the database of the Santo
pirito Hospital in Casale Monferrato, Alessandria, Italy. In
his administrative database all parameters related to pa-
ients followed in the Department of Urology are prospec-
ively recorded. At the time we performed the analysis, data
rom 129 patients withmetastatic prostate cancer (M1) were
vailable.
An economic model was developed with the TreeAge Pro
009 decision analysis software (TreeAge Software, Inc.,
illiamstown, MA), using a patient-level, microsimulation
echnique. Each branch of the decisional tree represents a
herapeutic option, and all branches have identical struc-
ures (Fig. 1). In the probabilistic, patient-level simulation,
ach patient is defined with unique characteristics of initial
ge, prostate-specific antigen (PSA) blood concentration,
nd Gleason score. Their initial values are defined in order
o reproduce the mean and standard deviation (SD) of the
tudied patient’s cohort (Table 1). Five identical “clones” are
ent through the five treatment branches. It is assumed that
he simulation starts as soon as the testosterone nadir is
eached, so that for each patient this value is constant and
otally dependent on the LHRH agonist treatment. The clin-
cal evolution of each single patient is defined by the pro-
ression between health states in a simple Markov chain
states of alive and dead). Until biochemical relapse occurs,
he patient is subjected only to natural mortality. After bio-
hemical relapse, a specific cancer-related mortality is
dded to the general population mortality. Current model-
ing guidelines recommend that the “cycle length of the
odel should be short enough so that multiple changes in
athology, symptoms, treatment decisions, or costs within
single cycle are unlikely” [8]. Clinical outcomes data used
disease progression and death; see next section) were re-
orted on a monthly basis, whereas other relevant time-
ependent parameters change more slowly (LHRH agonists
ere given every 3 months, with follow-up examinations
erformed every 6 months). Thus, we chose 1 month as the
lic price [24], €/package Ex-factory price, €/package
460.14 278.80
387.49 234.78
592.35 358.91
524.59 317.85
409.29 247.99Pubarkov cycle length.
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e derived the progression-free and total survival functions
y analyzing the outcomes data of the patient cohort using
ox semiparametric models. The Cox regression model ana-
yzes the influence of independent variables on event-free
urvival, under the assumption of proportional hazards,
hich means that the hazard ratio must be constant over
ime. We analyzed the data to find relationships between
aseline characteristics and the time of biochemical relapse
nd between those parameters and the total survival time
fter relapse.
The first Cox regression model was based on data from the
ohort of 129 metastatic patients (M1) and evaluated the time
o PSA elevation (biochemical relapse). The Gleason score, tes-
osterone level at nadir, PSA concentration (on a logarithmic
cale) 6 months after the start of LHRH agonist therapy, and
he age were considered as potential covariates. Except for
nitial age, all were significantly associated with the time to
rogression (Table 1).
The second Cox model was developed on a subset of 89
etastatic patients (M1) who had biochemical relapse, in
rder to evaluate cancer-related survival. The same set of
ovariates was tested for significant correlations, and initial
ge alone was again discarded because it was not statisti-
Table 5 – Tests and examinations costs.
Test/Examination Frequen
Medical examination plus DRE Every 6 mo
PSA and hematochemical examinations Every 6 mo
Bone densitometry Yearly
Cardiology evaluation (visit plus ECG) Yearly
Abdominal echography Every 6 mo
Bone scintigraphy (total body) Every 6 mo
Total
DRE, digital rectal examination; ECG, electrocardiogram; PSA, prostat
Table 6 – Base-case results: average (SD) effectiveness, cos
metastatic prostate cancer.
Leuprorelin
22.5 mg
Leup
11.
Effectiveness, months
Overall survival (SD) 60.31 (34.09) 59.4
Progression-free survival* (SD) 40.49 (41.42) 39.8
Costs, €
Hormone therapy (SD) 4857 (2670) 597
Follow-up (SD) 2809 (1522) 277
Chemotherapy (SD) 6315 (3116) 636
Total (SD) 13,981 (5150) 15,11
Cost-effectiveness, €/month lived
Cost-effectiveness 232
Incremental cost-effectiveness,
€/month of life gained
ICER vs. leuprorelin 22.5 mg NA Dom
ICER, incremental cost-effectiveness ratio; NA, not applicable; SD sta
* Undiscounted. Dominated: More costly and less effective than leuprorelally significant. In both models, the assumption of propor-
ional hazard for each included covariate was also verified.
The two Cox models were incorporated into the simula-
ion model. For each simulated patient, the probability of
isease progression and of cancer-related death was calcu-
ated as a function of Gleason score, PSA, and testosterone
evels. Natural mortality was factored as a competing risk as
function of age, and was derived from the mortality tables
f the general Italian population [9].
reatment effectiveness
o identify relevant publications for the estimate of the effec-
iveness of LHRH agonists in lowering testosterone levels, in
ay 2009 we performed a literature search in Medline using
he keywords “Gonadotropin-Releasing Hormone” [Mesh]
Testosterone/blood” [Mesh], with the limits “Clinical trial”
nd “Humans.” Abstracts of the 276 articles identified by this
trategy were checked for relevance by two of the authors (LP
nd MP), and full texts were obtained for 35 articles that were
udged by at least one of the authors to possibly contain infor-
ation regarding testosterone blood levels achieved. Manu-
lly searching the reference lists of these latter articles yielded
ne additional title. After examining the full text of these 36
apers, 20 studies conducted from 1990 to 2007 [10–29] were
Unit cost [25], € Annual cost, €
20.66 41.32
41.38 82.76
31.50 31.50
32.28 32.28
60.43 120.86
113.1 226.20
534.92
cific antigen.
d cost-effectiveness of LHRH agonists in the treatment of
lin
g
Goserelin Triptorelin Buserelin
75) 57.93 (32.93) 59.87 (33.99) 60.35 (34.15)
86) 38.40 (39.22) 40.19 (41.17) 40.57 (41.55)
9) 7405 (3943) 6804 (3604) 5428 (2825)
7) 2703 (1470) 2789 (1517) 2811 (1525)
1) 6472 (3058) 6341 (3108) 6307 (3121)
2) 16,579 (6133) 15,935 (5909) 14,546 (5277)
286 266 241
d Dominated Dominated 11,700
deviation.cy
nths
nths
nths
nthsts, an
rore
25 m
9 (33.
6 (40.
7 (313
2 (150
4 (310
4 (550
254
inate
ndard
in 22.5 mg.
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85V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 - 8 9dentified as reporting detailed data on the subject, some of
hem previously identified in a recent review by Novara et al.
6]. These studies evaluated goserelin (n 7), leuprorelin 7.5 or
2.5 mg (Eligard®; n  9), leuprorelin 3.75 or 11.25 mg (Enan-
one®; n  2), triptorelin (n  2), and buserelin (n  3).
All data (mean,median, SD,minimum-maximum, andper-
entile values) relating to the distribution of testosterone val-
es at nadir and the percentage of patients who reached the
estosterone cutoff point (almost always 50 ng/dl) were ex-
racted from these studies (Table 2) and meta-analyzed using
Bayesian randomeffectsmodel. In a randomeffectsmodel it
s assumed that the effects observed in different trials for the
ame drug can be ascribed to a common effect, which is then
nfluenced by peculiar conditions of each single study. The
esults of the meta-analysis, summarized in Table 1, were in-
orporated into the model to simulate the levels of testoster-
ne reached at nadir for each LHRH agonist.
osts
osts considered in the model include acquisition costs of
HRH agonists (Table 3)., based on ex-factory prices [30] and
oses recommended in the summary of product characteris-
ics (SPC), costs of monitoring tests and examinations, and
osts of chemotherapy for the hormone-refractory phase in
atients with biochemical relapse (Table 4).
Consumption of follow-up procedures was modeled ac-
ording to national guideline recommendations [4], and their
osts were assessed based on the national price lists for am-
ulatory services, which also include diagnostic examinations
Table 5) [31]. The cost of managing toxicities related to LHRH
gonist treatment was not included, assuming that this cost
ould not differ between strategies.
Resources consumed during chemotherapy were based on
ata from the randomized, controlled trial on hormone-re-
ractory prostate cancer patients reported by Tannock et al.
32]. Resources include drugs and administration of the che-
otherapy regimen (docetaxel plus prednisolone, for an aver-
ge of 9.5 cycles), premedication (corticosteroid plus anti-
metic agent), and drugs used for managing grades III to IV
Table 7 – Average (SD) life expectancy and progression-fre
Leuprorelin
22.5 mg
Months lived (SD) 60.31 (34.09)
Months free from biochemical relapse* (SD) 40.49 (41.42)
SD, standard deviation.
* Not discounted.
Table 8 – Average (SD) lifetime costs for each patient with t
Cost type Leuprorelin
22.5 mg
Leuprorelin
11.25 mg
Hormone therapy (SD), € 4856.87 (2670.25) 5977.07 (3138.5
Follow-up (SD), € 2809.05 (1521.93) 2772.40 (1506.5
Chemotherapy (SD), € 6315.29 (3115.62) 6364.41 (3101.1
Total (SD), € 13,981.21 (5150.10) 15,113.88 (5502.42)nemia and neutropenic fever (darbepoetin alfa 500g every 3
eeks for the first 9 weeks and 300 g every 3 weeks subse-
uently, and pegfilgrastim 0.6 mg every 3 weeks, respectively,
s recommended by the SPCs). The resulting total cost for
reating the terminal phase was estimated at €9475.58 and
as applied to all patients dying of cancer.
iscounting
talian guidelines for economic evaluations in health care is-
ued in 2001 recommend applying a 3% discount rate to both
uture costs and outcomes [33]. The same value has been in-
icated in themore recent proposal of guidelines for economic
valuation elaborated and discussed in 2009 by the Italian As-
ociation of Health Economics (AIES) [34]. Presently, the Euro-
ean Commission advocates a 5% rate in its current cost-ben-
fit guidance [35]. This rate is considered to be too high,
owever, by many economists [36], and the National Institute
or the Social Impact of Economy (Istituto Nazionale per
’Impatto Sociale dell’Economia, INISE) recommends a dis-
ount rate approximately 1.5% lower than the official social
iscount rate [37]. Thus, we chose to apply an annual discount
ate of 3.5% to both survival and costs.
robabilistic sensitivity analysis
he base case of the model is built to simulate the outcomes
nd costs for individual patients through themodel. Results of
he base case were calculated with 20,000 simulated patients.
haracteristics of each patient (age, PSA blood concentration,
nd Gleason score) were extracted from distributions repre-
enting the mean (SD) from the studied cohort of 129 meta-
tatic patients (M1) (Table 1).
A probabilistic sensitivity analysis was performed to take
nto account the uncertainty surrounding estimated parame-
ers of the two Coxmodels. This was accomplished by repeat-
ng 1000 cycles, each cycle with 5000 patient-level iterations.
ach cycle was characterized by a single value for each of the
arameters of the Cox models. These were randomly ex-
vival with the different considered treatments.
prorelin
1.25 mg
Goserelin Triptorelin Buserelin
.49 (33.75) 57.93 (32.93) 59.87 (33.99) 60.35 (34.15)
.86 (40.86) 38.40 (39.22) 40.19 (41.17) 40.57 (41.55)
onsidered treatments.
Goserelin Triptorelin Buserelin
7404.81 (3943.09) 6804.14 (3603.69) 5427.60 (2825.12)
2702.59 (1470.35) 2789.34 (1517.25) 2811.31 (1524.54)
6471.77 (3058.34) 6341.11 (3108.41) 6307.34 (3120.84)e sur
Leu
1
59
39he c
4)
0)
8)16,579.18 (6133.08) 15,934.60 (5909.45) 14,546.25 (5277.24)
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86 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 - 8 9racted from distributions representing the uncertainty of the
stimate (Table 1).
esults
ase case
urmeta-analysis showed that the lowest testosterone nadirs
ere achieved with buserelin and leuprorelin 22.5 mg (8–9
g/dl versus18 ng/dlwith goserelin; Table 1). Estimated total
urvival for metastatic patients was approximately 5 years,
ith amaximumdifference between treatment options of ap-
roximately 2 months (Table 6). The maximum difference be-
ween treatments for progression-free survival was almost 2
onths (Table 7).
The differences in the lifetime total costs of therapy were
ore pronounced, with a mean difference of nearly €2500
etween the least costly option (leuprorelin 22.5 mg) and
he most expensive (goserelin) (Tables 6 and 8). From the
erspective of cost-effectiveness, leuprorelin 22.5 mg had
he best cost/survival ratio, with a cost of approximately
230 per month (Table 6).
In the incremental cost-effectiveness analysis (Fig. 2),
euprorelin 22.5 mg dominated leuprorelin 11.25 mg, gos-
relin, and triptorelin, having greater effectiveness and
ower costs. Buserelin appeared more costly but slightly
ore effective than leuprorelin 22.5 mg. The incremental
ig. 2 – Comparative cost-effectiveness of five LHRH agonist
his representation, the higher the slope, the more cost-effe
ame cost.
Table 9 – Cost-effectiveness and incremental cost-effective
Leuprorelin
22.5 mg
Le
1
Cost-effectiveness, €/month lived 231.84
ICER vs. leuprorelin 22.5 mg,
€/month of life gained
DICER, incremental cost-effectiveness ratio. Dominated: more costly and leost-effectiveness ratio (ICER) of this drug (i.e., the cost re-
uired to obtain one additional unit of benefit) compared to
euprorelin 22.5mgwas about €12,000 per life-month gained
Table 9).
robabilistic sensitivity analysis
euprorelin 22.5 mg was the least costly drug in all 1000 sim-
lations, and, in terms ofmonths of life gained, only buserelin
asmore effective in a certain percentage of iterations (Fig. 3).
herefore, leuprorelin 22.5 mg consistently dominated leu-
rorelin 11.25 mg, goserelin, and triptorelin.
In Figure 3, the 1000 ICER values of buserelin versus leupro-
elin 22.5 mg are represented as a scatterplot on a cost-effec-
iveness plane. Points are all found in the northeast and
outheast quadrants. Points in the southeast quadrant repre-
ent a negative incremental survival gain of buserelin versus
euprorelin 22.5 mg, indicating that leuprorelin was superior
o buserelin in terms of both costs and effectiveness (domi-
ant). Buserelin never dominated leuprorelin, because its
osts were always higher.
ICER estimates of buserelin versus leuprorelin 22.5 mg
ere also plotted on a cost-effectiveness acceptability
urve, in which the probability of being cost-effective is rep-
esented as a function of increasing levels of willingness to
ay (WTP). As observed in Figure 4, there was a 100% chance
f leuprorelin 22.5 mg being cost-effective when WTP was
ulations in the treatment of metastatic prostate cancer. In
the treatment: better clinical results are obtained at the
with respect to leuprorelin 22.5 mg, in the base case.
relin
mg
Goserelin Triptorelin Buserelin
6 286.20 266.17 241.01
ated Dominated Dominated 11,700.22form
ctiveness
upro
1.25
254.0
ominss effective than leuprorelin 22.5 mg.
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87V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 - 8 9ess than €28,000 per life-year gained. Buserelin was cost-
ffective in more than 50% of cases only if the willingness to
ay was greater than €280,000 per life-year gained.
iscussion
t is well known that the different available formulations of
HRHagonists inducedifferent levels of testicular inhibition, but
linicians have not considered these differences to be clinically
elevant, provided that the castration threshold is achieved.
owever, as an analysis of recently published clinical data sug-
ests a continuous relationship between testosterone concen-
rations and disease progression, differences in the testosterone
adir achieved—even below the castration threshold—might
etermine variations in the rapidity of disease evolution and,
herefore, in survival.
ig. 3 – Scatterplot of the 1000 incremental cost-
ffectiveness ratio (ICER) estimates for buserelin versus
euprorelin 22.5 mg in the probabilistic sensitivity analysis.
shows the mean value of the cost-effectiveness ratio.
E, northeast; SE, southeast.
ig. 4 – Incremental cost-effectiveness acceptability curve fo
etastatic prostate cancer.In our analysis, estimated testosterone nadirs reached
ith different depot LHRH agonists were combined with
urvival functions obtained via Cox analysis of data from
etastatic patients in order to compare their cost-effective-
ess. Results obtained in the base case showed that there
ere some differences in mean overall survival and lifetime
osts with the different treatments. Leuprorelin 22.5 mg on
verage dominated all alternative options except buserelin, be-
ng associated with lower costs and higher effectiveness. In a
ensitivity analysis we explored the effect of the uncertainty on
he main model parameters. The mean lower cost and higher
ffectiveness of leuprorelin 22.5mg versus leuprorelin 11.25mg,
oserelin, and triptorelin was confirmed in all 1000 estimates.
userelin, on average, was more costly but more effective than
euprorelin 22.5 mg, with an ICER of approximately €12,000 per
ife-month gained in the base case.
An officialWTP threshold for the INHS is lacking. To assess
he value of a health intervention, results of pharmacoeco-
omic studies need, therefore, to be benchmarked against in-
ernational or conventional thresholds. In the literature, there
s a plethora of proposed cost-effectiveness thresholds, gen-
rally ranging from US$20,000/quality-adjusted life year
QALY) to the current £30,000/QALY applied in the United
ingdom [38–41]. The opportunity of raising this threshold is
onstantly under debate [42]; possibly the highest proposed
ost-effectiveness threshold is the three times per capita
ross domestic product (GDP) value suggested by the World
ealth Organization (WHO) in the WHO-CHOICE program for
fficient use of health resources [43].
In the probabilistic sensitivity analysis, leuprorelin 22.5
g had an 80% probability of being cost-effective in
omparison to buserelin even adopting this “extreme”
hreshold (equating to €78,000 based on Italy’s 2007 GDP per
apita [44]).
There is high variability in the differences in outcomes and
osts associatedwith the evaluated treatments in the patient-
evel simulations, which have distributions that are largely
verlapping. In contrast, consistent differences in mean sur-
ival and costs were seen in the probabilistic sensitivity anal-
erelin versus leuprorelin 22.5 mg in the treatment ofr bus
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88 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 - 8 9sis. We believe that this apparent discrepancy is related to
he simulation technique that we used, in turn reflecting the
ifferent type of uncertainty that the two analyses are de-
igned to reproduce. In the patient-level simulations, the vari-
bility reflects the interindividual heterogeneity and corre-
ponds to the low predictability of the outcomes of the single
atient. Themuch lower dispersion ofmean estimates shown
y the probabilistic sensitivity analysis, however, reflects the
ubstantial low sensitivity of mean, cohort-level outcomes to
he uncertainty in the parameters relating clinical character-
stics and outcomes, as estimated by the survival functions. In
ther terms, the clinical effect of the treatments, and more
enerally the outcomes, of the single patient are very unpre-
ictable. Indeed, it may well be possible that a patient treated
ith an LHRH agonist that is less effective than others on
verage does better than another similar patient treated with
drug that is on averagemore effective, whereas in a cohort of
atients the difference will emerge. These considerations fur-
her imply that the present results are relevant for decision
akers responsible for choices and budgets regarding cohorts
f patients—from the head of the department and hospital
rug purchaser to the policy makers at regional and national
evels—while having little or no importance for the clinician
eciding about the care of a single patient.
imitations
hemodel relationships between testosterone levels and can-
ermortality and progression are based on the analysis of data
rom one clinical center. The use of a continuous analytical
unction even for very low levels of the hormone implies the
bsence of a threshold below which testosterone stops stim-
lating cancer cell growth. Such a threshold is referred to as
astration level in earlier literature and its non existence
ight need to be further investigated and confirmed by larger
linical studies. The retrieval of the evidence on testosterone
adirs achieved with the available treatments might have
een more formally rigorous, although we believe that we
ave not omitted any crucial information. The findings of the
eview by Novara et al. [6] support this belief.
Regarding the cost side of the evaluation, some simplifica-
ions and approximations have been used. The national price
ist used for estimating the costs of follow-up diagnostic pro-
edures and examinations dates back to 1996; therefore, costs
re likely underestimated. The updating of price lists is the
esponsibility of the regions, but many of them have not com-
lied with this duty to date. For example, for the most expen-
ive of the diagnostic procedures considered in the present
odel (i.e., total body bone scintigraphy), only 10 of the cur-
ent 20 regional price lists have an updated value. The re-
orted mean of regional prices is of limited representative-
ess, because it neglects any weighting based on activity
olumes or target population. It is, however, higher than the
ld national price list [45]. The consequent underestimation of
ollow-up costs in the model may have slightly biased the
esults in favor of the strategies associated with longer sur-
ival. The cost of chemotherapy for the hormone-refractory
hase used in the calculations is also an aggregate estimate
hatmaynot reflect costs accurately. Nevertheless, all of theseosts are common to all treatments and the maximal mean
urvival difference between treatments is approximately 2
onths, so we are confident that the potential of these esti-
ates to bias the final results is very limited.
onclusions
espite some limitations, our analysis represents the first at-
empt to summarize the available evidence regarding the rel-
tive effectiveness of testosterone-lowering therapies in met-
static prostate cancer and their consequences on hard
utcomes into one comprehensive conceptual scheme. The
esults suggest that leuprorelin 22.5mg is themost cost-effec-
ive of the available depot LHRH agonists in the Italian setting.
lthough only tentative conclusions can be drawn, based on
odeling with meta-analysis of comparative survival data,
ur findings should provide valuable guidance for decision
akers who need to make rational choices regarding the use
nd price of LHRH agonists in Italian patients with metastatic
rostate cancer—like the hospital pharmacist, the head of the
rology department, or the regional agency deciding on hos-
ital drug formularies.
cknowledgment
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